It's being allocated to Alexion, AstraZeneca's rare disease group.
AstraZeneca's site in Westmeath is set to benefit from a new €65 million investment by the company.
The money will be allocated to the organisation's Rare Disease group, Alexion, which is based in Monksland, Athlone.
It will be used to install new drug substance production equipment and warehousing facilities.
The total €65 million will be shared between site's in Athlone, Blanchardstown and College Park.
Minister for Trade Promotion, Digital and Company Regulation and Longford-Westmeath Fianna Fáil TD, Robert Troy said, “I am delighted that Alexion has announced further investment in its Dublin and Athlone sites. This news further cements Ireland’s reputation as a global centre of excellence for life sciences. I am particularly delighted to see continued investment in Athlone, and further endorses the midlands as an excellent place to invest, work and live.”
Independent Roscommon-Galway TD Denis Naughten said, “This announcement is a further vote of confidence in the Monksland site which will expand Alexion’s drug substance production capabilities in Athlone and is a boost to the reputation of the area as a key biopharmaceutical hub in the Country.”
Funeral Arrangements Announced For Woman Killed In Midlands Crash
Garda Commissioner Confident Security Operation For EPC Meeting Will Be A Success
Midlands Gardaí Appeal For Witnesses To Fatal Crash
Midlands Security & Defence Analyst Says Hoax Bomb Threats Aimed To Intimidate
Almost €446,000 Allocated To Midlands Community Centres And Clubhouses
Midlands Family Takes On Ireland’s Fittest Family Challenge
5K Fundraiser To Support Motor Neurone Disease Association Takes Place In Westmeath